Lv41
600 积分 2025-05-20 加入
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
18天前
已完结
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies
1个月前
已完结
Type 2 calreticulin mutations activate ATF6 to promote BCL-xL-mediated survival in myeloproliferative neoplasms
1个月前
已完结
Marginal-Zone Lymphomas
1个月前
已完结
Marginal-Zone Lymphomas
1个月前
已完结
Oxaliplatin-related side effects: Characteristics and management
1个月前
已关闭
Cost-effectiveness analysis of glofitamab versus rituximab for relapsed or refractory diffuse large B-cell lymphoma patients in China
1个月前
已完结
Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis
1个月前
已完结
Outcomes of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma Treated With R‐GemOx: A Multicenter Cohort Study
1个月前
已完结
Erythroid-predominant myelodysplastic neoplasms exhibit a distinct genomic landscape with poor outcomes after venetoclax-based therapy
2个月前
已完结
皖公网安备34019202002308
